C
Christopher D. Lao
Researcher at University of Michigan
Publications - 127
Citations - 24365
Christopher D. Lao is an academic researcher from University of Michigan. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 35, co-authored 100 publications receiving 17710 citations.
Papers
More filters
Journal ArticleDOI
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
Alexi Vasbinder,YeeAnn Chen,Adrien Procureur,Allison Gradone,Tariq U. Azam,Daniel C. Perry,Husam Shadid,Elizabeth Anderson,Tonimarie Catalan,Pennelope K. Blakely,Namratha Nelapudi,M. Fardous,Marie Bretagne,Sarah Adie,Kristen Pogue,Monika Leja,Sarah Yentz,Bryan J. Schneider,Leslie A. Fecher,Christopher D. Lao,Joe-Elie Salem,Salim S. Hayek +21 more
TL;DR: In this article , the authors examined biomarker trends of patients on ICI and their association with the incidence of ICI myocarditis and outcomes and found that ICIMyocarditis is a dreaded and unpredictable complication of immune checkpoint inhibitors (ICI).
Journal ArticleDOI
Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety.
John E. Hanks,Kevin J. Kovatch,S. Ahmed Ali,Emily Roberts,Alison B. Durham,Joshua D. Smith,Carol R. Bradford,Kelly M. Malloy,Philip S. Boonstra,Christopher D. Lao,Scott A. McLean +10 more
TL;DR: Long-term follow up indicates that SLNB showcases durable accuracy, safety, and prognostic importance for cutaneous HNCM, and immunosuppression was the only factor significantly associated with regional recurrence.
Journal ArticleDOI
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic,Michael R. Migden,Nicole Basset-Seguin,Claus Garbe,Anja Gesierich,Christopher D. Lao,Christopher J. Miller,Laurent Mortier,Dedee F. Murrell,Omid Hamid,Jorge F. Quevedo,Jeannie Hou,Edward McKenna,Natalie Dimier,Sarah Williams,Dirk Schadendorf,Axel Hauschild +16 more
TL;DR: Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete.
Journal ArticleDOI
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Asim Amin,Mohammed M. Milhem,Georgina V. Long,Christopher J. Hoimes,Theresa Medina,Robert M. Conry,Christopher D. Lao,Gregory A. Daniels,Sunil Reddy,Robert H.I. Andtbacka,Minal A. Barve,Montaser Shaheen,Thomas Tueting,Michael Chisamore,Emmett V. Schmidt,Albert Candia,Cynthia Chinedu Obiozor,Erick Gamelin,Robert Janssen,Antoni Ribas +19 more
TL;DR: SD-101 is a synthetic CpG-ODN agonist of TLR9 that stimulates dendritic cells to release IFN-alpha and mature into antigen presenting cells - activating T cell anti-tumor responses.
Journal ArticleDOI
CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
Jedd D. Wolchok,V. Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,J.-J. Grob,Charles Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,R. Dummer,A. Hill,John B. A. G. Haanen,Michele Maio,Grant A. McArthur,Arvin Yang,Linda Rollin,Christine Horak,James Larkin,F.S. Hodi +19 more